JPMorgan Chase & Co. Grows Stock Holdings in Diversified Healthcare Trust (NASDAQ:DHC)

JPMorgan Chase & Co. raised its position in shares of Diversified Healthcare Trust (NASDAQ:DHC - Free Report) by 42.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,233,790 shares of the real estate investment trust's stock after buying an additional 369,984 shares during the period. JPMorgan Chase & Co. owned about 0.51% of Diversified Healthcare Trust worth $2,838,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in DHC. Proficio Capital Partners LLC purchased a new stake in shares of Diversified Healthcare Trust in the 4th quarter worth about $44,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Diversified Healthcare Trust in the 4th quarter worth about $76,000. Quantbot Technologies LP lifted its position in shares of Diversified Healthcare Trust by 64.4% in the 4th quarter. Quantbot Technologies LP now owns 34,175 shares of the real estate investment trust's stock worth $79,000 after purchasing an additional 13,388 shares during the period. Intech Investment Management LLC lifted its position in shares of Diversified Healthcare Trust by 132.4% in the 4th quarter. Intech Investment Management LLC now owns 103,558 shares of the real estate investment trust's stock worth $238,000 after purchasing an additional 59,006 shares during the period. Finally, Thrivent Financial for Lutherans purchased a new position in Diversified Healthcare Trust during the 4th quarter valued at about $243,000. Hedge funds and other institutional investors own 75.98% of the company's stock.

Analyst Upgrades and Downgrades

DHC has been the topic of several research reports. B. Riley initiated coverage on shares of Diversified Healthcare Trust in a research note on Thursday, April 3rd. They set a "buy" rating and a $4.50 price objective on the stock. StockNews.com raised shares of Diversified Healthcare Trust from a "sell" rating to a "hold" rating in a research note on Thursday, April 10th.

Diversified Healthcare Trust Stock Up 2.2 %

Shares of NASDAQ DHC traded up $0.05 during midday trading on Monday, hitting $2.32. The stock had a trading volume of 620,117 shares, compared to its average volume of 991,168. The business's 50 day moving average is $2.43 and its 200-day moving average is $2.55. The company has a market cap of $559.67 million, a P/E ratio of -1.44 and a beta of 2.02. Diversified Healthcare Trust has a 52 week low of $2.00 and a 52 week high of $4.24. The company has a quick ratio of 11.57, a current ratio of 11.57 and a debt-to-equity ratio of 1.44.

Diversified Healthcare Trust (NASDAQ:DHC - Get Free Report) last issued its earnings results on Tuesday, February 25th. The real estate investment trust reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.31. The firm had revenue of $379.62 million for the quarter, compared to the consensus estimate of $370.97 million. Diversified Healthcare Trust had a negative net margin of 26.09% and a negative return on equity of 17.55%.

Diversified Healthcare Trust Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 22nd will be paid a $0.01 dividend. The ex-dividend date of this dividend is Tuesday, April 22nd. This represents a $0.04 annualized dividend and a dividend yield of 1.72%. Diversified Healthcare Trust's dividend payout ratio is presently -2.60%.

About Diversified Healthcare Trust

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants.